Evolus (EOLS) vs Ovid Therapeutics (OVID)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Ovid Therapeutics (OVID) has outperformed Evolus (EOLS) over the past year, gaining 57.1% versus a loss of 4.8%. Over five years, EOLS leads with a +14.4% price change compared with -32.5% for OVID. Evolus is the larger company by market cap ($431.5 million vs $415.2 million), about 1.0 times the size, while Ovid Therapeutics is growing revenue faster (+1181.3% vs +11.6%).
Evolus converts more of its revenue into profit, with a net margin of -17.4% versus -240.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EOLS | OVID |
|---|---|---|
| Share price | $6.52 | $2.20 |
| Market cap | $431.55M | $415.21M |
| 1-day change | -6.86% | -5.98% |
| YTD return | -1.95% | +34.97% |
| 1-year return | -4.82% | +57.14% |
| 5-year return | +14.39% | -32.52% |
| Forward P/E | 22.68 | — |
| EPS (TTM) | $-0.48 | $-0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $297.18M | $7.25M |
| Revenue growth (YoY) | +11.61% | +1181.27% |
| Net income (latest FY) | $-51.64M | $-17.41M |
| Gross margin | 66.33% | — |
| Operating margin | -10.99% | -585.20% |
| Net margin | -17.38% | -240.13% |
| 52-week high | $9.31 | $3.11 |
| 52-week low | $3.86 | $1.26 |
| Distance from 52-week high | -29.97% | -29.15% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +136.20% | +179.55% |
| Average volume | 925.77K | 1.98M |
| Shares outstanding | 66.19M | 188.73M |
| Employees | 365 | 23 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OVID has outperformed EOLS by 62.0 percentage points over the past year.
- Evolus is more profitable, keeping -17.4 cents of every revenue dollar as net income versus -240.1 cents for Ovid Therapeutics.
- Ovid Therapeutics grew revenue faster in its latest fiscal year (+1181.27% vs +11.61%).
About Evolus
EOLS stock →Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.
Health Care · Biotechnology: Pharmaceutical Preparations · 365 employees
About Ovid Therapeutics
OVID stock →Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
EOLS vs OVID FAQ
Which is bigger, Evolus or Ovid Therapeutics?
Evolus (EOLS) is larger, with a market capitalization of $431.55M compared with $415.21M for Ovid Therapeutics (OVID).
Which stock has performed better over the past year, EOLS or OVID?
OVID returned +57.14% over the past 12 months, compared with -4.82% for EOLS (price return, excluding dividends). Past performance does not predict future results.
Are Evolus and Ovid Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.